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Abstract
Objective—To present common language for defining adherence of infrequent yet repeated health
behaviors.
Methods—We illustrate methodological and conceptual issues using human papillomavirus (HPV)
vaccination and screening mammography study data as examples.
Results—Adherence rates of infrequent, repeated behaviors varied widely depending on how
adherence was defined and measured. We advocate use of 3 standard definitions of adherence:
initiation of behavior (initiation), adherence to most recent opportunity (on-schedule), and timely
adherence across multiple opportunities (maintenance or completion).
Conclusions—The proposed framework has cross-cutting implications for research and practice.
Standardizing adherence metrics may facilitate comparisons across studies of health behaviors
practiced at infrequent yet repeated intervals.
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Introduction
Researchers have studied adherence extensively in the context of behaviors that many people
practice frequently (eg, daily), such as flossing teeth, eating a low-fat diet, exercising, smoking
cessation, and taking oral birth control medications.1–3 For these behaviors, studying
adherence can yield voluminous data. Even when using standardized instruments, researchers
often must categorize people as “adherent” and “nonadherent,” to make measurement
practicable, analyses tractable, and study findings more easily communicated.
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Adherence in the context of infrequent health behaviors has received relatively less attention.
By infrequent, we refer to behaviors that people typically perform monthly or less often, such
as receiving A1C tests every 3 months for blood glucose levels, having Pap tests every one to
3 years, or getting flu shots annually. These infrequent behaviors must be repeated to gain the
full health benefits they offer. Although studying infrequent, repeated behaviors often yields
fewer data points than dose study of frequently performed behaviors, it has inherent
complexities that deserve attention.
Researchers have lamented the absence of a gold standard for measuring adherence for most
health behaviors. For example, medication adherence can be assessed using patients’ self-
reports, electronic medication monitors, unannounced pill counts, pharmacy records,
biological assays, and so on.4 Our focus here is on providing standard definitions of adherence
(ie, using data to identify people who are adherent), rather than standardizing measurement
instruments (ie, how to collect data). To define adherence for infrequent behaviors, we advocate
adopting common language. This suggestion is consistent with recommendations from a
conference on cancer screening sponsored by the National Cancer Institute, Centers for Disease
Control, and American Cancer Society that recommended standardization of screening-
adherence measures.5–7
We propose 3 broad categories: initiation, on-schedule, and maintenance. Initiation refers to
a person’s having ever engaged in the behavior. An example is whether a person has ever
received flu vaccine. On-schedule refers to adhering to guidelines at the most recent
opportunity to engage in the behavior, such as whether a person had a flu shot during the last
flu season. Cutoffs for defining on-schedule use should come from evidence-based
recommendations regarding how often the behavior should be practiced, such as those from
the US Preventive Services Task Force8 or the American Cancer Society.9 Maintenance (or
completion) refers to adherence across multiple, previous opportunities, again, based on
evidence-based recommendations. An example is whether a person had flu shots during the
last 5 flu seasons. Assessing maintenance (or completion) should incorporate assessments of
behavior at several time points as well as their timeliness. Some of these adherence distinctions
are stated in stage theories of health behavior and diffusion of innovations theory.10–12
Our adherence categories reflect the shift that occurs as health behaviors are introduced and
subsequently diffused over time (Figure 1). By diffusion, we refer to the processes by which
innovations become adopted in populations over time.12 For new health behaviors in early
stages of diffusion and, thus, not yet adopted by most people, studying initiation may be the
most appropriate focus for research. For example, studies of the relatively new nasal flu spray
vaccine have assessed initiation. As a behavior becomes more established, researchers should
begin studying on-schedule adherence to guidelines. Maintenance can be studied only when a
behavior is well established in a population. Most likely, there always will be population
pockets that have not yet adopted the behavior.
To illustrate implications of our proposed definitions of adherence in greater depth, we use
examples of human papillomavirus (HPV) vaccination and mammography screening, using
data from our research. These 2 behaviors represent different regions of the diffusion curve;
HPV vaccination is a new health behavior whereas mammography is an established health
behavior. HPV vaccination may prevent infection with HPV whereas mammograms are a
screening test to find breast cancers early. To achieve potential benefits of early detection,
women need regular mammograms. Thus, maintenance of the behavior is the desired end state.
In contrast, HPV vaccination is complete when people have obtained the recommended doses.
Although we focus on these 2 examples, the issues are relevant to other infrequent, repeated
behaviors.
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Example 1: HPV Vaccination
HPV vaccination may reduce the incidence of cervical cancer, perhaps by as much as 77%
with widespread vaccine coverage,13 while also reducing genital warts and perhaps other HPV-
related cancers.14 The US Advisory Committee on Immunization Practices (ACIP)
recommends females aged 11 to 12 years routinely receive the vaccine, with catch-up
vaccinations for females aged 13 to 26.15 The quadrivalent HPV vaccine requires 3 doses over
6 months, administered at months zero, 2, and 6 and may confer lifelong protection.15 This
report focuses on quadrivalent HPV vaccine for females, but the definitions we propose can
be extended to other ACIP recommendations (eg, bivalent HPV vaccine for females and
quadrivalent HPV vaccine for males).16
Once people have completed the 3-dose series, over a relatively brief period, it is likely they
will not have to be vaccinated again for a long time, if ever. In this regard, the HPV vaccine
regimen is similar to other vaccine regimens (eg, hepatitis B vaccine). It also is similar to
regimens for some prophylactic medications (eg, prophylactic malaria medications taken
weekly: a week before arriving in a malaria area, while being there, and for 4 weeks after
leaving it).
The main challenges for defining HPV vaccine adherence are accounting for the number and
timing of vaccine doses received. We present several approaches to defining HPV vaccine
adherence that shift in relevance as diffusion of vaccination increases: initiation, on-schedule,
and completion. We illustrate the issues using HPV vaccination data from the Carolina HPV
Immunization Measurement and Evaluation (CHIME) Project. One component of CHIME was
a population-based longitudinal study to investigate HPV vaccine decision making by parents
of adolescent girls in an area where women are at relatively high risk of cervical cancer.
Interviewers completed baseline telephone surveys with 889 (73%) of 1220 eligible parents
between July and October 2007.17 Of 873 baseline respondents eligible for follow-up, 650
(74%) completed follow-up telephone interviews between October and November 2008.
Sampling and data collection methods are reported in detail elsewhere.17 Because some parents
may have been unfamiliar with HPV vaccine, we provided all parents with informative
statements about HPV and HPV vaccine during baseline interviews. Percentages reported
below are weighted to account for the study’s complex sampling design. The Institutional
Review Board for the University of North Carolina approved this research.
HPV vaccine initiation
Studying initiation is a logical place to begin research for a new behavior like HPV vaccination.
HPV vaccine initiation compares people who have received one or more doses to those who
have received none at a certain time point (but met eligibility criteria for vaccination). Because
HPV vaccination only recently became available, most published studies reporting HPV
vaccine uptake have focused on initiation.18–29
Assessing HPV vaccine initiation has numerous advantages. First, collecting data on initiation
minimizes both interviewer and respondent burden because initiation can be assessed with a
single item. A recent statewide survey of parents in North Carolina used such an item: “Has
[child] had any shots of the HPV vaccine?” 30 Second, assessing vaccine initiation may be less
prone to errors than other adherence definitions because it does not rely on the exact number
of doses received or their timing. Parental reports of their daughters’ HPV vaccination histories
may be especially susceptible to errors, as parents may not recall the number of doses their
child has received,31 especially if they have more than one child in the approved age range for
vaccination. Last, HPV vaccine initiation allows for straightforward analyses and parameter
interpretation because vaccination status is treated as a dichotomous variable.
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The main limitation to assessing vaccine adherence as initiation is loss of information that
occurs when grouping all vaccinators together. A female who has received 2 doses of HPV
vaccine, with her second dose a month prior to data collection (ie, she is on-schedule), might
be grouped with a female who has received 2 doses, with her second dose a year before data
collection (off-schedule). Thus, the complexity is lost, although population-level
characterization is gained.
In the CHIME baseline survey conducted a little over a year after HPV vaccine became
available in the United States, 12% (83/650) of parents said their daughters had initiated the
HPV vaccine series. Of parents whose daughters had not been vaccinated at baseline, an
additional 27% (149/567) reported vaccination during follow-up interviews the next year.
Thus, 36% (232/650) of parents said their daughters had initiated the 3-dose HPV vaccine
series by the end of the study. If we examined vaccine initiation using these data, the 232
parents who reported their daughters had received one or more doses would be compared to
the remaining 418 parents of daughters who were classified as not vaccinated.
On-schedule for HPV vaccine regimen completion
Although HPV vaccine initiation is a good place to begin research on this new behavior, it does
not address vaccination timeliness. For unvaccinated people, this means getting a first dose.
For those with one or 2 doses, this means getting the next dose after some period of months.
On-schedule adherence includes 2 categories: (a) on-schedule, initiated regimen and within
recommended time guidelines to complete regimen or completed regimen (all 3 doses received)
and (b) off-schedule, not initiated vaccine regimen (no doses received) or initiated regimen but
outside of recommended time guidelines to complete regimen. Guidelines for timeliness should
be based on the ACIP guidelines in the United States.15
Although the ACIP recommendations address the timing of doses, they do not specify how
long past these milestones people can wait before they should be considered off-schedule. In
CHIME, Brewer and colleagues classified adolescent girls who had received one or 2 doses
within guidelines if they were not more than 2 months past the time recommended for receiving
their next dose at follow-up interviews (ie, within 4 months after the first shot or 6 months after
the second shot at the time of follow-up interviews) (Figure 2). Allowing a window beyond a
due date is similar to the way other repeat health behaviors are treated for classification
purposes.32–34
One advantage of categorizing use as on-schedule is that it accounts for adherence to guidelines
about dose timing. Assessing vaccine initiation evaluates only whether people had the first
dose. On-schedule adherence may provide a more accurate depiction of participants’
vaccination status, especially if many people who initiate do not complete the vaccination
series. Similar to assessing vaccine initiation, this approach results in straightforward analyses
and parameter interpretation because it treats vaccination as a dichotomous outcome.
A disadvantage to this approach is additional burden on survey participants to accurately recall
number and timing of doses received. Many participants will be unable to recall this
information, leading to concerns about how to classify them. Failure to accurately recall this
information may be especially problematic for assessing HPV vaccine adherence, as some
individuals may be unaware of the recommended number and timing of doses. Moreover,
failure to recall does not necessarily mean the person was not vaccinated. This is especially
challenging when relying on proxy respondents. In CHIME, the inability of participants to
recall when their daughters received HPV vaccine doses was a common problem; many parents
were unable to provide even the year the dose was administered for 42% (232/553) of reported
doses. Individuals with unknown vaccination dates for their most recent doses were classified
as off-schedule unless (a) they reported receiving all 3 doses (because regimen completion is
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considered on-schedule regardless of vaccination schedule) or (b) they reported receiving 2
doses and gave a vaccination date for their first dose that was within 6 months of the follow-
up interview. Electronic health records, physicians’ reports, and insurance data may provide
viable alternatives (or validation sources) to self- or parent-reported vaccination histories. Such
objective sources may lessen missing or inaccurate data. Some of these sources were used in
past studies reporting HPV vaccination levels, though levels of missing data were not provided.
19,22,35 Objective sources also have limitations, eg, delays in receiving reports from physicians’
office, which may render electronic data incomplete.32
Using the proposed classification scheme, 31% (197/650) of females would be classified as
on-schedule [parents reported their daughters had completed the HPV vaccine regimen (21%,
137/650) or had received one or 2 doses but were on-schedule to complete the regimen (10%,
60/650)], and 69% (453/650) would be considered off-schedule [had received one or 2 doses
but were off-schedule to complete the regimen (5%, 35/650) or had not initiated the HPV
vaccine regimen (64%, 418/650)].
HPV vaccine regimen completion
HPV vaccine may be most effective when people receive all 3 doses in a timely manner.15
Thus, completion of all 3 doses most clearly addresses public health goals. Analyses compare
people who have completed all doses to others who have not initiated vaccination or who have
initiated but not completed. People who achieve initiation or on-schedule adherence do not
fully meet public health guidelines. However, at this time, it is premature to expect HPV
vaccine completion as the outcome in most current studies. Series completion is relatively rare
(only 21% in the CHIME Project), a reflection of difficulties in availability of HPV vaccine
and insurance coverage for it, as well as the relatively large number of people initiating the
vaccine who have not yet received all 3 doses.25,35 As barriers to HPV vaccination decrease
over time, it will become increasingly relevant to examine rates of regimen completion as the
appropriate outcome for behavioral interventions.
Example 2: Mammography Screening
Secondary prevention via mammography is the most effective way to reduce breast cancer
morbidity and mortality.36 Regular use of mammography can lead to early diagnosis of breast
cancer, when tumors are smaller and cancer is potentially curable; and patients also may have
more treatment options.36 Mammography use provides a contrast to HPV vaccination. First,
it represents screening rather than primary preventive action. Second, it is at a very different
state of diffusion compared to HPV vaccination.
Mammography screening requires women to repeat the same behavior at regular but infrequent
intervals, potentially over decades. In this way, mammography screening is similar to other
types of cancer screening (eg, colon, cervical) and wellness visits (eg, eye exams, dental
cleanings). That is, they all are based on the premise that people will practice these behaviors
on regular schedules that may range from months to years apart. The issues discussed here
regarding mammography screening may apply to these other health behaviors.
Defining mammography adherence encounters considerable challenges in incorporating the
number and timing of mammograms.37 Defining adherence is further complicated by the
different guidelines of organizations and the manner in which they change over time. Although
some national organizations recommend women receive screening every one to 2 years (eg,
National Cancer Institute), other organizations recommend every year (eg, American Cancer
Society, American College of Radiology). Despite a recent push to standardize operational
definitions of mammography use, none have been widely adopted at this time.33,34 It is not yet
clear what effect the recent US Preventive Services Task Force statement about biennial
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screening mammography will have on the guidelines of different organizations or on the
practices of women and their physicians.37
We present several approaches to define adherence that reflect diffusion of mammography
over time: initiation, on-schedule use, and maintenance. To illustrate these definitions, we use
mammography screening data from PRISM (Personally Relevant Information on Screening
Mammography). PRISM is a 4-year National Cancer Institute-funded intervention study of
mammography adherence as part of the Health Maintenance Consortium. The eligible sample
frame included North Carolina women between age 40 and 75 who were enrolled with the
North Carolina State Health Plan for Teachers and State Employees, had mammograms 8 to 9
months before baseline surveys, and were due for subsequent mammograms 2 to 3 months
after recruitment. PRISM enrolled 3547 women in 2003 and followed them annually until
2008. Details of the study can be found elsewhere.32 Institutional review boards for the
University of North Carolina and Duke University approved this research.
For these analyses, we use the 2003 American Cancer Society guidelines in effect at the time
of the study that recommend annual screening for women 40 and over.9 In defining adherence,
we allow a 14-month window, typical in this research, to account for potential scheduling
difficulties and other reasonable delays.32–34 We use 12-, 24-, and 36-month telephone survey
data and claims data across 3 annual screening cycles.
Mammography initiation
As women in the United States began adopting screening mammography, a research priority
was to identify the proportion of women who had ever received screening (initiation) and to
compare women who had been screened to those who had not been screened. Although
initiation of mammography use is still a concern among certain subgroups (eg, recent
immigrants, women in certain economic strata, countries with underdeveloped medical
infrastructure), mammography use has been disseminated widely in the United States.38 In the
late 1970s, less than 10% of women reported ever having had mammograms.39 By the early
1990s, almost 90% of age-appropriate women reported having had at least one mammogram.
39,40 The successful diffusion of mammography requires a shift in focus from initiation to
timely use, especially for populations with insurance. On-schedule use and maintenance
provide better markers of potential population benefit than does initiation. Indeed, PRISM
recruited only women who had their last screening mammograms between September 2003
and September 2004, to ensure all were adherent to recent mammograms upon study entry.
This was consistent with the NIH Health Maintenance Consortium interest in behavioral
maintenance (http://hmcrc.srph.tamhsc.edu/default.aspx).
On-schedule mammography use
A natural next step from assessing initiation is to examine whether women are on-schedule for
mammography screening. On-schedule mammography use compares women who have had
recent mammograms to those who have not. Many national surveys (eg, Behavioral Risk Factor
Surveillance System-BRFSS, Health Information Trends Survey) and intervention trials define
mammography adherence as on-schedule use, assessed as having had mammograms within a
defined time.41–43 One item can efficiently measure on-schedule use, reducing participant
burden. For example, BRFSS uses “How long has it been since your last mammogram?”44
Assessing on-schedule use is valuable in evaluating the immediate impact of interventions. For
national studies, on-schedule use is an indicator, in cross-section, of progress toward meeting
national guidelines. In clinical settings, measuring on-schedule use alerts health care providers
whether patients are up-to-date on screening tests. This is a critical quality indicator for
Healthcare Effectiveness Data and Information Set (HEDIS) and other quality assessments.
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Finally, on-schedule use is computationally simple and easy to interpret via parameter
estimates of a dichotomous outcome (on-schedule vs off-schedule).
However, defining mammography as on-schedule use has several limitations. First, on-
schedule use does not necessarily take into account past screening behavior. Thus, women
classified as on-schedule may include women with different patterns of prior mammography
use.7 Similarly, the off-schedule group may include never screeners and lapsed screeners. Each
type of mammography use is conceptually different, may have unique behavioral correlates,
and may require different behavioral interventions. Combining these groups could mask
important differences. Appropriate interventions to encourage women who have lapsed from
regular mammography use may be different from those needed to motivate women to initiate
use. Last, self-reports of use over long periods of time can cause forward telescoping of
screening dates, resulting in overestimations of on-schedule use.45 Claims data may be a viable
alternative to self-reported use for women with insurance coverage. However, these data often
are incomplete due to lag time in claims processing, women’s paying out of pocket, or filing
claims with other insurance plans not captured in the study (eg, spouse/partner insurance).
In PRISM, 90% (3049/3406), 91% (3096/3406), and 89% (3040/3406) of participants
confirmed they had mammograms in the 14 months prior to the 12-, 24- and 36-month surveys,
respectively, and would be classified as on-schedule. (These proportions exclude 141 women
with missing outcome data.) At each survey, women who had recent mammograms (on-
schedule) would be compared to women who had mammograms more than 14 months ago
(off-schedule). These proportions are likely to overestimate how many women are getting
mammograms at regular intervals, as on-schedule use does not take into account the interval
between recent and prior screenings.
Mammography maintenance
Like most screening tests, mammography is most effective when at-risk populations are
screened at regular intervals. Accordingly, it is important to know what proportion of age-
eligible women have received mammograms at regular intervals over time (maintenance). This
is the most compelling public health outcome. Below we illustrate 3 ways to define
mammography maintenance and some of the associated strengths and weakness of each
approach.
Maintenance as number of mammograms
One approach to operationalizing maintenance counts how often women receive screening
mammograms at recommended intervals over time. For example, maintenance may be defined
as having completed 3 screening mammograms at 14-month intervals. Women then are
categorized as having achieved maintenance (3 mammograms) or not (0, 1, 2 mammograms).
Many studies have used count measures of mammography screening to assess
maintenance33,34; however, few studies have included more than 2 on-schedule mammograms
in the definition of maintenance. Using the counts approach reflects the interval between
screenings. For this reason, it is preferable for measuring widely diffused behaviors compared
to assessments of on-schedule use.
Mammography-adherence definitions that do not incorporate the interval between screenings
address recurring instances of on-schedule use, not maintenance. For example, women could
be on-schedule (defined as having had a mammogram in the previous 14 months) at interviews
a year apart. However, some of these women may not be in maintenance, because
mammograms that were classified as on-schedule with respect to interview dates were more
than 14 months apart from one another.
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In PRISM, 52% (1782/3406) of participants received 3 consecutive mammograms at 14-month
intervals and, thus, would be classified as having achieved maintenance. This estimate is similar
to other reported estimates of screening mammography use over multiple screening
opportunities.33,34 On average, PRISM participants received 2.2 screening mammograms over
the study. Ideally, they would have received 3 mammograms.
Defining maintenance as having achieved some number of screening mammograms has
limitations. First, assessment of maintenance requires detailed information about timing of
mammograms so researchers can calculate if women received mammograms at recommended
intervals. Women can get off-schedule for many reasons, and not all reflect nonadherence. For
example, some abnormal test results may cause women to obtain their next mammograms
sooner than would have occurred following a normal test result. Second, many women will
have missing data, which requires decisions about how to deal with these data. Count measures
may not account for variability in predictors of use over time. Lastly, defining adherence as a
binary outcome can lose important information. For example, PRISM participants who
received 3 screening mammograms (n = 1782) would be compared to a group comprising
women who received no (n = 366), one (n = 475) or 2 mammograms (n = 783), which implicitly
assumes the latter 3 groups are homogeneous.
Maintenance as time off-schedule
Time off-schedule is another count method for defining mammography maintenance. Off-
schedule time can be calculated by counting the number of days of nonadherence. Each day
beyond the defined screening interval contributes an additional day to the nonadherence tally
until a participant receives a subsequent mammogram. Unlike counting numbers of completed
mammograms, this approach is more sensitive to smaller variations in adherence.
Time off-schedule suffers from some of the same limitations as defining adherence as the
number of screening mammograms, such as attrition and more complex data collection. Data
may be highly skewed, with many cases having the same number of days nonadherent. Time
off-schedule may classify some women with different use patterns as having the same level of
nonadherence. A woman with 365 days off-schedule could represent someone who skipped a
year of screening, delayed each of her mammograms by 4 months, or some other permutation.
Thus, the summary measure may mask differences that are clinically meaningful.
Using PRISM data, we calculated the number of days women were nonadherent (based on a
14-month window between screenings). On average, women experienced 80 days nonadherent
over the study (standard deviation [SD] = 148, range 0 – 672). However, 58% of women did
not have any days nonadherent, which resulted in right-skewed data.
Modeling maintenance as event onset
Another approach is to define maintenance over time as event onset, such as not receiving the
next consecutive screening mammogram when it should have been received. Survival analysis
includes statistical methods to assess the occurrence and timing of events.46,47 In survival
analysis, an event is a change identified as happening at a specific time. Survival analysis is
commonly used to model onset of disease or recovery after treatment. Like other ways of
defining mammography use, different approaches to operationalization can have considerable
effects on the inferred rate of mammography use,48 and computations require detailed
information on the timing of events.49 Survival analysis offers some advantages over other
methods of modeling mammography maintenance. Attrition is handled by censoring at the
point of withdrawal from the study. In addition, survival models produce estimates of the effect
of time on the outcome, which may be important for behaviors repeated over decades.
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Using a form of survival analysis called discrete event history analysis,52 we can model the
onset of nonadherence to sustained mammography screening over 3 consecutive screening
opportunities or intervals. Estimates include information for 141 women with missing data
until they withdrew from study or had missing data (ie, were censored). In PRISM, 26% (n =
921) were nonadherent in the first interval; in interval 2, an additional 15% were not adherent
(n = 538); and in the last interval, another 9% became nonadherent (n = 306). Thus, only 50%
(n = 1782) had sustained use over 3 years (ie, completed 3 consecutive screening
mammograms). When we modeled the effect of time on mammography maintenance, we
observed a strong effect for number of years (odds ratio [OR]=0.71, 95% confidence interval
[CI]: 0.66–0.76). That is, people who remained adherent in later periods were less likely to
become nonadherent.
DISCUSSION
In the early stages of diffusion, people may be unaware of a new behavior, or barriers to access
may prevent action. Therefore, the emphasis of research should be on motivating people to try
evidence-based recommended health innovations. Over time, as awareness increases, barriers
fall, and more people adopt the health behavior, focus should shift to assessing timely, repeated
use. We suggest 3 standard adherence definitions for infrequent yet repeated behaviors:
initiation, on-schedule, and maintenance or completion. As new health behaviors are found to
have public health benefit, it is appropriate to start with measures of initiation and later focus
on assessing maintenance. Similarly, when well-accepted technologies are being introduced
to other populations, there should be a natural progression of adherence measures. Although
we have focused on mammography screening and HPV vaccination, our 3 adherence
definitions may be useful for many other behaviors.
Each of our proposed adherence categories has strengths and weaknesses. Although assessing
behavioral initiation is useful in early stages of behavioral diffusion, it lacks detail on the
timeliness of the behavior. On-schedule use takes into account some of the timeliness needed
to accurately evaluate adherence. However, it oversimplifies past use accounting for only the
most recent opportunity to engage in the behavior and not intervals between behaviors.
Maintenance addresses these concerns, but it requires detailed data on patterns of use. This can
create substantial burden on participants, analysts, and budgets due to such considerations as
repeated assessments or multiple data sources. Nevertheless, as more nonobtrusive measures,
such as electronic medical records, become available, data collection will be less of a problem.
Each of the 3 adherence definitions risks errors of misclassification. Measures that incorporate
timeliness, however, may be less susceptible to some forms of misclassification compared to
adherence defined as some arbitrary cutoff. Lastly, not all health behaviors neatly fall into the
categories of frequent or infrequent. Condom use is a frequent occurrence for some people and
rare for others depending on how often sex occurs.
The diffusion perspective can guide decisions about appropriate interventions. For example,
mass media interventions may be efficient and effective when an innovation is new, knowledge
of the behavior is low, and few people have adopted the innovation, because mass media can
reach large portions of the public with health information.50 As innovations like mammography
become standard practice and more widely accepted, people who have not yet adopted
screening may need more intensive personal approaches to become motivated or overcome
barriers. More research is needed on how barriers differ across initiation, on-schedule use, and
maintenance or completion so that we can personalize intervention approaches.
Our proposed adherence definitions have cross-cutting implications for research and practice.
Adopting uniform definitions may be useful in fostering uptake of common metrics of
adherence. Common adherence metrics may facilitate comparison across studies of health
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behaviors that occur at infrequent yet repeated intervals.34 Research reports, however, should
provide detailed information about how adherence is defined, measured, and modeled, because
these methods can considerably affect variation in estimates.47 Common adherence definitions
also can guide the field, potentially prompting research on on-schedule, maintenance, and
completion as diffusion progresses and these adherence definitions become more relevant.
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Recommended Definition of Adherence Depends on How Widely People Have Adopted the
Health Behaviora
a Adapted from Rogers E.M., Diffusion of Innovation. 4th ed. New York: The Free Press;
1995.
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